职位描述
岗位职责：
1、负责制定喜滴克区域市场策略，评估和推动各项市场计划和活动的执行；
2、负责在所辖区域收集和反馈市场竞争状况、分析产品关键卖点；
3、负责区域内学术会议的组织和执行工作，并做好区域KOL的维护；
4、负责对区域销售人员进行药学及医学专业知识和市场策略培训及指导；
5、负责制作区域内销售团队推广需要的学术推广资料。
任职资格：
1、本科及以上学历，医药类相关专业；
2、5年以上市场管理经验；
3、具有优秀的团队协作能力及较好的执行力，抗压力强。
企业简介
企业介绍
ENTERPRISE PROFILE
泰凌总部位于香港，在上海、北京、广州设有投资、营销管理、研发及医学事务中心，在苏州、泰州、长沙及瑞士建有生产基地。目前，集团拥有20余家子公司。
NT PHARMA'S HEADQUARTER IS BASED IN HONG KONG WHICH INCLUDES INTERNATIONAL BUSINESS AND INVESTMENT GROUP. MARKETING MANAGEMENT, RESEARCH AND DEVELOPMENT AND MEDICAL BUSINESS CENTRES ARE BASED IN SHANGHAI, BEIJING,AND GUANGZHOU. OUR PRODUCTION AND MANUFACTURING FACTORIES ARE BASED IN SUZHOU, TAIZHOU, CHANGSHA AND SWITZERLAND. CURRENTLY NT PHARMA GROUP HAS MORE THAN 20 SUBSIDIARIES.
集团的核心产品覆盖了肿瘤及血液系统疾病、骨代谢疾病、消化系统疾病、中枢神经系统疾病、呼吸系统疾病等多个治疗领域，主要有：国际著名骨科品牌“密盖息”(鲑鱼降钙素)，国家1.1类肿瘤新药“喜滴克”（尿多酸肽注射液），国家肝病新药“松栀丸”，品牌仿制药“舒思”（富马酸喹硫平片）等20余种产品。这些药品覆盖了中国除西藏、台湾以外的广大地区，近20,000家医疗机构，并受到中国医疗机构的广泛认同。
WE FOCUS ON DEVELOPMENT OF CORE PRODUCTS OF OUR BRAND COVERING TUMOUR AND BLOOD SYSTEM DISEASES, DIGESTIVE SYSTEM DISEASES, CENTRAL NERVOUS DISEASES, DISEASES OF RESPIRATORY SYSTEM AND OTHER THERAPEUTIC FIELDS. OUR MAIN PRODUCTS INCLUDES: WORLD RENOWNED ORTHOPAEDIC BRAND "MIACALCIC" (SALMON CALCITONIN), NATIONAL 1.1-CLASS NEW TUMOR DRUG "XIDIKE" (UROACITIDES INJECTION), NATIONAL HEPATIC NEW DRUG "SONGZHI PILL", BRAND GENERIC DRUG "SHUSI" (FUMARIC ACID QUETIAPIEN TABLETS) AND 20+ OTHER PRODUCTS. OUR PRODUCTS HAVE BEEN DISTRIBUTED BY MORE THAN 20,000 MEDICAL INSTITUTIONS ALL OVER CHINA EXCEPT FOR TIBET AND TAIWAN AND IS WIDELY RECOGNIZED BY CHINESE MEDICAL INSTITUTIONS.
泰凌自创建以来，一直致力于成为面向世界的国际化医药企业，“密盖息”远销世界20余个国家地区，“舒思”远销欧洲市场。同时，与诸多世界领先跨国医药企业建立了长期战略合作关系，包括葛兰素史克(GSK)、辉瑞(Pfizer)、罗氏(Roche)、诺华(Novartis)、贝朗(B|BRAUN)等。
SINCE OUR ESTABLISHMENT, NT PHARMA HAS BEEN DEVOTED TO BECOME A WORLD-ORIENTED INTERNATIONALIZED PHARMACEUTICAL ENTERPRISE. "MIACALCIC" HAS BEEN USED IN MORE THAN 20 COUNTRIES AND REGIONS. "SHUSI" HAS ITS STRONG MARKETS IN EUROPE MARKET MEANWHILE NT PHARMA HAS MANY LONG-TERM STRATEGIC COOPERATION RELATION WITH WORLD LEADING MULTINATIONAL PHARMACEUTICAL ENTERPRISES INCLUDING GLAXOSMITHKLINE (GSK), PFIZER, ROCHE, NOVARTIS AND BIBRAUN.
[展开全文]
[收缩全文]
